BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
IVDs on the rise
Radiopharmaceuticals
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, September 25, 2023
See today's BioWorld Asia
See today's BioWorld
Home
» South Korea’s Genexine begins phase I/IIa trials for COVID-19 vaccine
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
South Korea’s Genexine begins phase I/IIa trials for COVID-19 vaccine
June 23, 2020
By
David Ho
and
Gina Lee
No Comments
HONG KONG – South Korea-based Genexine Inc. has started enrolling a phase I/II trial for a DNA vaccine targeting COVID-19 called GX-19.
BioWorld
BioWorld Asia
Clinical
Coronavirus
Vaccine
Asia-Pacific
